Comparative Pharmacology
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARESTOCAINE HYDROCHLORIDE versus LIDOCAINE HYDROCHLORIDE 0 8 AND DEXTROSE 5 IN PLASTIC CONTAINER.
ARESTOCAINE HYDROCHLORIDE vs LIDOCAINE HYDROCHLORIDE 0.8% AND DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Lidocaine is an amide-type local anesthetic that stabilizes the neuronal membrane by inhibiting sodium ion channels, thereby blocking the initiation and conduction of nerve impulses. It also has antiarrhythmic properties by decreasing automaticity in Purkinje fibers and suppressing ventricular arrhythmias.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
Intrathecal administration for spinal anesthesia: 50-100 mg (1.5-2 mL of 5% solution) as a single dose. For continuous epidural or peripheral nerve block, 0.8% solution with dextrose 5% is not typically used; refer to 1-2% lidocaine without dextrose for continuous infusion.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Terminal elimination half-life: 1.5-2 hours (adults); prolonged in heart failure (up to 5-8 hours) or hepatic impairment (up to 10-15 hours). Clinically, context indicates redistribution half-life ~8 minutes.
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Renal (metabolites: 4-hydroxyxylidine, glycylxylidide, monoethylglycinexylidide; <10% unchanged). Biliary/fecal negligible.
Category C
Category A/B
Local Anesthetic
Local Anesthetic / Antiarrhythmic (Class Ib)